Skip to content
value.today

Angiocrine Bioscience, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2012
Total raised
$64 M
3 rounds on record
Latest round
$2 M
Aug 2025
First round on record
Mar 2013
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Angiocrine Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2025$2 MNo. 3$2 to $10 million

Angiocrine Bioscience, Inc.: Raise no. 3, Aug 2025

Investors in this round

16 investors had bought by the notice of Sep 5, 2025: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John R Jaskowiak · Executive Officer · Chief Operating Officer/Secretary
  • John T Lomoro · Executive Officer · Chief Financial Officer/Treasurer
  • Paul W Finnegan · Executive Officer, Director · President/Chief Executive Officer
  • David L Parkinson · Director
  • Jeffrey L Port · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul W. Finnegan, M.D., President and CEO. Source: SEC Form D, newest notice filed Sep 5, 2025. Read the notice at the SEC.

equitySEC
Oct 2021$58 MNo. 2$50 to $250 million

Angiocrine Bioscience, Inc.: Raise no. 2, Oct 2021

Investors in this round

78 investors had bought by the notice of Oct 15, 2021: 78 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$58 M of $99 M offered; $41 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,422,553
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Jaskowiak · Executive Officer · Chief Operating Officer, Secretary
  • John Lomoro · Executive Officer · Chief Financial Officer
  • Paul Finnegan · Executive Officer, Director · Chief Executive Officer
  • David Parkinson · Director
  • Jeff Jonas · Director
  • Jeffrey Port · Director
  • Marc Cohen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BOFA SECURITIES, INC. (CRD 283942) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “accounts for potential fees payable on subsequent closings”

Signed by John Lomoro, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 15, 2021. Read the notice at the SEC.

equitySEC
Mar 2013$4 MNo. 1$2 to $10 million

Angiocrine Bioscience, Inc.: Raise no. 1, Mar 2013

Investors in this round

1 investor had bought by the notice of Mar 13, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Claude Geoffrey Davis, Ph.D. · Executive Officer, Director
  • John Geoffrey Klacking, Ph.D. · Executive Officer, Director
  • Brad Geoffrey Daniel · Director
  • Jeffrey L. Port, M.D. · Director
  • Rick Geoffrey Murdock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by C. Geoffrey Davis, Ph.D., Secretary. Source: SEC Form D, newest notice filed Mar 13, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Angiocrine Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2025).

    SEC Form D · Sep 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2025

That is all the official record says: Angiocrine Bioscience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Angiocrine Bioscience, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 78 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Angiocrine Bioscience, Inc.
NameRoleNamed in
John R JaskowiakChief Operating Officer/SecretarySep 2025
John T LomoroChief Financial Officer/TreasurerSep 2025
Paul W FinneganPresident/Chief Executive OfficerSep 2025
John JaskowiakChief Operating Officer, SecretaryOct 2021
John LomoroChief Financial OfficerOct 2021
Paul FinneganChief Executive OfficerOct 2021
Claude Geoffrey Davis, Ph.D.Executive officerMar 2013
John Geoffrey Klacking, Ph.D.Executive officerMar 2013
David L ParkinsonDirectorSep 2025
Jeffrey L PortDirectorSep 2025
Paul W FinneganPresident/Chief Executive OfficerSep 2025
David ParkinsonDirectorOct 2021
Jeff JonasDirectorOct 2021
Jeffrey PortDirectorOct 2021
Marc CohenDirectorOct 2021
Paul FinneganChief Executive OfficerOct 2021
Brad Geoffrey DanielDirectorMar 2013
Claude Geoffrey Davis, Ph.D.DirectorMar 2013
Jeffrey L. Port, M.D.DirectorMar 2013
John Geoffrey Klacking, Ph.D.DirectorMar 2013
Rick Geoffrey MurdockDirectorMar 2013